Treatment of Hyperthyroidism
For overt hyperthyroidism from Graves' disease or toxic nodules, use methimazole as first-line medical therapy for 12-18 months, with radioactive iodine ablation or total thyroidectomy as definitive alternatives based on patient-specific factors. 1
Treatment Options for Overt Hyperthyroidism
The three primary treatment modalities are antithyroid drugs (ATDs), radioactive iodine (RAI) ablation, and thyroidectomy. 2, 3
Antithyroid Drug Therapy
- Methimazole (MMI) is the preferred ATD for initial treatment of Graves' disease, administered for 12-18 months. 1
- In children with Graves' disease, extend MMI treatment to 24-36 months. 1
- Switch to propylthiouracil (PTU) when planning pregnancy and during the first trimester due to MMI's teratogenic risk. 1
- If TSH-receptor antibodies remain persistently elevated at 12-18 months, either continue MMI for another 12 months or proceed to definitive therapy (RAI or surgery). 1
- For patients who relapse after completing ATD course, definitive treatment is recommended, though long-term low-dose MMI is an acceptable alternative. 1
Radioactive Iodine Ablation
- RAI is the most widely used treatment in the United States for hyperthyroidism. 3
- RAI is absolutely contraindicated in patients with active/severe thyroid eye disease (TED). 1
- For patients with mild TED, RAI can be used but requires steroid prophylaxis with short-course low-dose prednisone, especially if TED is recent-onset or risk factors for progression exist. 4, 1
- In moderate-to-severe active TED, avoid RAI; use ATDs or thyroidectomy instead. 4
- Recent evidence raises concern about increased risk of secondary cancers following RAI treatment. 5
Thyroidectomy
- Total thyroidectomy is indicated for Graves' disease and toxic multinodular goiter; thyroid lobectomy suffices for toxic adenomas. 5
- Surgery should be performed by a high-volume, experienced thyroid surgeon for cost-effectiveness and optimal outcomes. 1, 5
- Specific indications for surgery include: concurrent thyroid cancer, pregnancy, compressive symptoms (dysphagia, orthopnea, voice changes), and Graves' disease with ophthalmopathy. 2, 5
- Preoperatively, establish euthyroid state with ATDs and control cardiovascular manifestations with beta-blockers. 5
Treatment of Subclinical Hyperthyroidism
- Treatment is recommended for patients at highest risk: those older than 65 years or with persistent TSH <0.1 mIU/L. 2
- Subclinical hyperthyroidism is associated with atrial fibrillation, osteoporosis, fractures, and dementia. 6
- Post-hoc analysis from randomized trials shows that normalizing TSH decreases atrial fibrillation risk. 6
- The degree of TSH suppression is critical for clinical assessment and treatment decisions. 6
Special Populations and Situations
Thyroid Eye Disease Considerations
- In moderate-to-severe active TED, ATDs are preferred, with thyroidectomy as a valid alternative. 4
- RAI should generally be avoided but may be used with extreme caution if aggressive TED treatment with high-dose glucocorticoids (with or without orbital radiotherapy) is administered simultaneously. 4
- In sight-threatening TED, control hyperthyroidism with ATDs until TED is cured—this is the absolute priority. 4
Pregnancy Management
- Women on MMI must switch to PTU when planning pregnancy and throughout the first trimester. 1
- Beta-blockers should be used to manage cardiovascular manifestations (hypertension, tachycardia) to prevent significant cardiovascular events. 5
Critical Pitfalls to Avoid
- Never use RAI in patients with active/severe thyroid eye disease without appropriate steroid prophylaxis and careful risk assessment. 4, 1
- Do not continue MMI in the first trimester of pregnancy due to teratogenic effects. 1
- Ensure patients are euthyroid before thyroidectomy to prevent thyroid storm, a rare but life-threatening complication requiring multidisciplinary management. 5
- Recognize that untreated hyperthyroidism causes cardiac arrhythmias, heart failure, osteoporosis, adverse pregnancy outcomes, and increased mortality. 2